Themis Medicare Ltd. Navigates Headwinds with Strategic Focus and Profitability Turnaround in Q3 FY26

Themis Medicare Limited, a prominent player in the Indian pharmaceutical sector, recently unveiled its financial results for the third quarter and nine months ending FY26. Despite facing some significant top-line pressures and disruptions in a key business segment, the company has demonstrated remarkable resilience, reporting a positive turnaround in profitability for Q3 FY26. This period highlights the management's strategic agility in optimizing operations and focusing on high-growth areas amidst challenging market conditions.

For Q3 FY26, Themis Medicare reported a consolidated revenue of ₹90.13 crore. While this represents a slight year-on-year decrease of 3.9% from ₹93.81 crore in Q3 FY25, the profitability metrics tell a more encouraging story. The company's EBITDA grew by 14.9% year-on-year to ₹9.80 crore, up from ₹8.53 crore in the corresponding quarter last year. This improvement was largely driven by effective cost rationalization measures, which boosted the EBITDA margin by 178 basis points to 10.87%. Furthermore, Profit After Tax (PAT) saw an extraordinary surge, increasing by 1843.7% to ₹10.09 crore in Q3 FY26 from a mere ₹0.52 crore in Q3 FY25, with PAT margin expanding to 11.20%.

However, the nine-month period (9M FY26) presented a more challenging picture, with net revenue declining by 20.4% to ₹265.71 crore from ₹333.81 crore in 9M FY25. This was accompanied by negative EBITDA of ₹(3.37) crore and a negative PAT of ₹(7.74) crore, reflecting the cumulative impact of earlier disruptions and sluggishness in certain segments.

Strategic Business Performance and Future Outlook

Dr. Sachin Patel, Managing Director & CEO, acknowledged the